Cameron Haswell

Mr. Cameron Haswell

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
CHCameron Haswell
Cameron Haswell
Ajmol AliAjmol Ali
Ajmol Ali
Rachel A. PageRachel A. Page
Rachel A. Page
RHRoger Hurst
Roger Hurst
Kay Rutherfurd-MarkwickKay Rutherfurd-Markwick
Kay Rutherfurd-Markwick
Metabolic syndrome (MetS) is a group of metabolic abnormalities, which together lead to increased risk of coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM), as well as reduced quality of life. Dietary nitrate, betalains and anthocyanins may improve risk factors for MetS and reduce the risk of development of CHD and T2DM. Beetroot is a rich source of dietary nitrate, and anthocyanins are present in high concentrations in blackcurrants. This narrative review considers the efficacy of beetroot and blackcurrant compounds as potential agents to improve MetS risk factors, which could lead to decreased risk of CHD and T2DM. Further research is needed to establish the mechanisms through which these outcomes may occur, and chronic supplementation studies in humans may corroborate promising findings from animal models and acute human trials.

17 August 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
CHCameron Haswell
Cameron Haswell
Kay Rutherfurd-MarkwickKay Rutherfurd-Markwick
Kay Rutherfurd-Markwick
RHRoger Hurst
Roger Hurst
MWMarie Wong
Marie Wong
HMHajar Mazahery
Hajar Mazahery
Rachel A. PageRachel A. Page
Rachel A. Page
Background/Objectives: Health challenges associated with metabolic syndrome (MetS) have stimulated investigations into the effectiveness of nutraceutical interventions, including beetroot juice (BRJ), in mitigating MetS risk factors. Methods: This repeated-measures crossover trial (n = 16 healthy participants) investigates the effects of daily ingestion of two different BRJs [United Kingdom beetroot juice (UKBR), 1280 mg nitrate, 147 mg betalains; New Zealand beetroot juice (NZBR), 1120 mg nitrate, 506 mg betalains] and placebo (PL) on plasma nitrate and nitrite levels, MetS biomarkers and systemic vascular resistance (SVR). Participants consumed the juices for 6 days, with measures taken on day 7 fasted (pre-dose) and 2 h and 5 h post ingestion (acute). Results: On day 7, pre-dose plasma nitrate levels were significantly elevated for UKBR and NZBR compared to PL (297.2, 177.1 and 64.2 µmol/L, respectively). On day 7, UKBR achieved significantly higher plasma nitrate levels 2 h and 5 h post consumption than NZBR (2 h: 750.3 vs. 577.7 µmol/L; 5 h: 703.4 vs. 510.1 µmol/L) and PL at all timepoints. Plasma nitrite was elevated pre-dose for UKBR only and for both juices relative to PL at 2 h and 5 h. On day 7, pre-dose systolic blood pressure (SBP) was significantly lower for NZBR than PL (−4.96 mmHg) and 2 h post-ingestion for both UKBR (−5.63 mmHg) and NZBR (−4.98 mmHg) compared with PL. Systemic vascular resistance was 11.6% lower after 6 days of consumption of NZBR relative to PL (ratio 0.884, 95% CI 0.803 to 0.974). Conclusions: Supplementation with BRJ reduced SBP relative to placebo, and the betalain-rich NZBR also reduced SVR, whereas the higher-nitrate UKBR did not. This suggests that betalains and nitrates may play an important role in these improvements. The Australia New Zealand Clinical Trials Registry ID for this study is: ACTRN12622000714785.

10 July 2022
Verified
Conference Paper
Closed access
CHCameron Haswell
Cameron Haswell
Introduction Currently, more than 463 million people are living with diabetes; a number predicted to rise to 578 million by 20301. As type 2 diab |